Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/11/2019 09/12/2019 09/13/2019 09/16/2019 09/17/2019 Date
72.4(c) 72.8(c) 72.65(c) 74.21(c) 75(c) Last
1 499 675 1 150 512 1 152 202 1 025 311 989 473 Volume
-1.62% +0.55% -0.21% +2.15% +1.06% Change
More quotes
Financials (USD)
Sales 2019 1 694 M
EBIT 2019 -98,1 M
Net income 2019 -85,7 M
Finance 2019 402 M
Yield 2019 -
Sales 2020 1 947 M
EBIT 2020 62,2 M
Net income 2020 48,1 M
Finance 2020 533 M
Yield 2020 -
P/E ratio 2019 -157x
P/E ratio 2020 283x
EV / Sales2019 7,71x
EV / Sales2020 6,64x
Capitalization 13 460 M
More Financials
Company
BioMarin Pharmaceutical specializes in the development, production, sales and marketing of biopharmaceutical products. Net sales break down by source of income as follows: - sale of medications (96.7%): designed to treat problems caused by overactive lysosomal enzyme activity,... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
09/09BIOMARIN PHARMACEUTICAL : to Participate in Morgan Stanley 17th Annual Global He..
PR
08/28BIOMARIN PHARMACEUTICAL : to Participate in Morgan Stanley 17th Annual Global He..
PR
08/02BIOMARIN PHARMACEUTICAL : Management's Discussion and Analysis of Financial Cond..
AQ
08/01BIOMARIN : 2Q Earnings Snapshot
AQ
08/01BIOMARIN PHARMACEUTICAL INC : Results of Operations and Financial Condition, Fin..
AQ
07/16BIOMARIN TO HOST SECOND QUARTER 2019 : 30pm ET
PR
07/10BIOMARIN PHARMACEUTICAL INC : Change in Directors or Principal Officers (form 8-..
AQ
07/09BIOMARIN PHARMACEUTICAL : Appoints Pharmaceutical Veteran and Former J & J Execu..
PU
07/08BIOMARIN PHARMACEUTICAL : Plans Regulatory Submissions for Marketing Authorizati..
PR
06/27BIOMARIN PHARMACEUTICAL : Announces Acceptance of Late Breaking Abstract at the ..
AQ
More news
Analyst Recommendations on BIOMARIN PHARMACEUTICAL IN
More recommendations
Sector news : Biopharmaceuticals
04:46pALEXION PHARMACEUTICALS : Names New Finance Chief
DJ
03:38pU.S. Senators urge FTC to scrutinize multi-billion dollar pharma mergers
RE
10:33aABBVIE : Form 8.3 - Allergan Plc
DJ
08:18aBAYER : Invests $20 Million in U.S.-Based Informed Data Systems
DJ
07:15aMerck Gets FDA Priority Review for Investigational Ebola Zaire Virus Vaccine
DJ
More sector news : Biopharmaceuticals
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL IN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 117,22  $
Last Close Price 75,00  $
Spread / Highest target 121%
Spread / Average Target 56,3%
Spread / Lowest Target 6,67%
EPS Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Daniel K. Spiegelman Chief Financial Officer & Executive Vice President
Eduardo E. Von Pervieux Chief Information Officer & Vice President
Geoffrey M. Nichol Senior Vice President & Chief Medical Officer
Elaine J. Heron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICAL INC.-12.85%13 318
CSL LIMITED24.59%71 654
BIOGEN INC.-21.54%43 552
ALEXION PHARMACEUTICALS10.31%24 338
GRIFOLS16.64%17 681
SAMSUNG BIOLOGICS CO LTD--.--%16 399